Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
Cutting-edge mRNA technology is breaking new ground, offering hope for targeted treatments in autoimmune conditions beyond infectious diseases.
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
Already a subscriber? Log in